Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group.
Miyawaki
S
S
Kobayashi
T
T
Tanimoto
M
M
Kuriyama
K
K
Murakami
H
H
Yoshida
M
M
Minami
S
S
Minato
K
K
Tsubaki
K
K
Omoto
E
E
Oh
H
H
Jinnai
I
I
Sakamaki
H
H
Hiraoka
A
A
Kanamaru
A
A
Takahashi
I
I
Saito
K
K
Naoe
T
T
Yamada
O
O
Asou
N
N
Kageyama
S
S
Emi
N
N
Ueda
T
T
Tomonaga
M
M
Ohno
R
R
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003561:Cytarabine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D007970:Leukopenia / Q000139:chemically induced; D011446:Prospective Studies
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine